Cargando…
A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
Therapeutic targeting of advanced or metastatic non-small-cell lung cancer (NSCLC) represents a major goal of clinical treatment. Polo-like kinase 1 (PLK1) is an essential mitotic kinase in cell cycle progression and is associated with oncogenesis in a large spectrum of cancer types, including NSCLC...
Autores principales: | Li, Lifeng, Xue, Wenhua, Shen, Zhibo, Liu, Jie, Hu, Min, Cheng, Zhenyong, Wang, Yuxing, Chen, Yulu, Chang, Hao, Liu, Yingyi, Liu, Bin, Zhao, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369516/ https://www.ncbi.nlm.nih.gov/pubmed/32728610 http://dx.doi.org/10.1016/j.omto.2020.06.013 |
Ejemplares similares
-
The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
por: Hao, Bing-bing, et al.
Publicado: (2020) -
De-Novo Design
of Cereblon (CRBN) Effectors Guided
by Natural Hydrolysis Products of Thalidomide Derivatives
por: Heim, Christopher, et al.
Publicado: (2019) -
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
por: Jones, J. R., et al.
Publicado: (2021) -
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019) -
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
por: Thakurta, A, et al.
Publicado: (2014)